Gut microbial pathways linked to brain chemistry in 61 women

A stool sample and a noninvasive brain scan gave researchers two views of the same 61 people. In a study published in Molecular Psychiatry, teams from the University of Surrey and the University of Roehampton linked the genetic capacity of gut microbes to levels of GABA and glutamate in the brains of 61 healthy women aged 17–25.

GABA is a chemical messenger that predominantly dampens neural activity, while glutamate promotes excitation. Their relationship, known as the excitatory/inhibitory balance, is involved in neuroplasticity, cognition and mental health. Researchers used shotgun metagenomic sequencing to identify microbial pathways involving GABA, glutamate, short-chain fatty acids and other neuroactive compounds, then used proton magnetic resonance spectroscopy to measure brain chemistry in three regions.

The links depended on where the researchers looked. The inferior occipital gyrus, a visual-processing region used as a comparison area, showed associations with the broadest range of microbial pathways, including glutamate degradation and GABA metabolism. The anterior cingulate cortex showed a different pattern involving microbial glutamate and propionate pathways, while the dorsolateral prefrontal cortex had a more selective association with a GABA-production pathway.

The same data also connected some microbial pathways with self-reported well-being. A GABA-related pathway was associated with trait and social anxiety; tryptophan-metabolism pathways were associated with depressive symptoms and social anxiety; and a propionate-production pathway was associated with poorer sleep quality. The researchers stress that these are associations, not evidence that a particular bacterium causes anxiety or directly changes a brain chemical.

So what, concretely? The work gives researchers specific microbial functions and brain regions to test rather than treating the gut–brain axis as one simple pathway. It does not yet support changing someone’s microbiome to treat anxiety, depression or sleep problems. The study measured genetic potential, not the metabolites actually produced, and its cross-sectional design cannot establish direction or causality; larger longitudinal and intervention studies are still needed.